• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sigma-Tau

edit

Sigma-Tau is actively pursuing partnerships to commercially develop products that address the unmet medical needs of patients with rare diseases.

They offer their partners an experienced management team, core competencies in the global development and commercialization of products for rare diseases, and a strong financial position.

Recent Milestones

edit

• 
  Sigma-Tau invested in Soligenix. (6/16/10)
  Posted 7/7/10 at 1:18am via dorbiopharma.com
• 
  Sigma-Tau acquired Enzon Pharmaceuticals for $327M. (11/9/09)
  Posted 1/21/10 at 4:33am via sigmatau.com

Videos

Screenshots

edit

Sources

1. ENZON ANNOUNCES AGREEMENT TO SELL SPECIALTY PHARMACEUTICAL BUSINESS (sigmatau.com) [edit]
2. Soligenix Announces Private Equity Financing of $5.16 Million with its Partner Sigma-Tau and other Institutional Investors (dorbiopharma.com) [edit]